UNITED THERAPEUTICS CORP.

Company Snapshot

Founded: 1996

Entity Type: Public

Employees: 1,400

Region: U.S.

Revenue: $3,182.7 Millions

Revenue Year: 2025

Headquarter: Maryland, U.S.

Key Geographics: U.S., Rest of the World

Corporate Address: 1000 Spring Street Silver Spring, Maryland 20910 U.S. Tel. +1-301-608-9292 www.unither.com

Company Overview

United Therapeutics Corp. is a U.S.-based biotechnology company focused on treatments for pulmonary arterial hypertension and other severe heart conditions. Its core business involves developing, manufacturing, and marketing therapies that improve blood flow in the lungs and reduce strain on the heart.

United Therapeutics Corp.’s cardiovascular portfolio includes prostacyclin and prostacyclin pathway therapies for pulmonary hypertension. Its key products include Remodulin, an injectable prostacyclin analog; Tyvaso and Tyvaso DPI, inhaled therapies for pulmonary arterial hypertension and pulmonary hypertension linked to interstitial lung disease; Orenitram, an oral prostacyclin therapy; and Adcirca, an oral treatment that helps relax pulmonary blood vessels. These medications are used in both hospital and outpatient settings and are appropriate for patients at various stages of disease severity.

Financial Highlights (FY 2025)

Net Revenue: ***

Total Current Liabilities: ***

Total Current Assets: ***

R&D expenses: ***

Operating Income: ***

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member